4 thoughts on “Pharmaceutical companies crazy monkeys! Experimental monkey is 160,000 yuan. How does this monkey develop?”
Juan
The agile monkeys in the zoo often attract children to watch. However, in addition to watching, the use of monkeys in medicine should not be underestimated. However, recently, the value of the monkeys has risen again and again, and many pharmaceutical companies shouted: “Can’t afford it!” According to the comprehensive report of Zhongxin Jingwei, due to the increased demand for research and development of pharmaceutical companies under the epidemic, coupled with the long cultivation cycle of monkey cultivation, and every time the cultivation cycle was cultivated, and every time the cultivation cycle was cultivated, and every time the cultivation cycle was cultivated, and every time the cultivation cycle was cultivated, each It can only be used for the study of one disease, which led to a 22 -fold increase in the price of experimental monkeys within 4 years, soaring from less than 7,000 yuan before, soaring to the current 160,000 yuan. The relevant data shows that at present, there are only about 30,000 domestic experimental monkeys, and the voice of “valuable monkeys” in the market is getting louder. Affected by the “monkey shortage”, many companies began to hoard the monkey speed, and even bought the monkey field directly. It is reported that in 2020, Yaoming Kant’s wholly -owned subsidiary acquired the Guangdong Chunsheng Monkey Farm and harvested more than 20,000 crab and monkeys. According to the data of the Cat Cat, the registered capital of Wuxi Pharmaceutical Kant New Pharmaceutical Development Co., Ltd. is RMB 24,505.1572 yuan, and its operating business includes the development of research and approval of new drugs, medicine intermediates and fine chemical products (excluding dangerous chemicals) research and development (excluding dangerous chemicals) and many more.
In June 6, Zhaoyan New Pharmaceutical (603127.SH; 06127.HK) announced that Yingmao Bio became a wholly -owned subsidiary, and 20,000 experimental monkeys will gradually be returned to Zhao Yan Under the name of the new medicine. According to the data of Cat Cat, the registered capital of Beijing Zhaoyan New Pharmaceutical Research Center Co., Ltd. is 2708.2039 million yuan, and its business includes biological products, biotechnology technology development, technology transfer, and so on. There are only about 30,000 domestic experimental monkeys, and the voice of “valuable monkeys” in the market is getting louder. Affected by the “monkey shortage”, many companies began to hoard the monkey speed, and even bought the monkey field directly. At the expense of the blood speed of the monkey, in order to give self -sufficiency, it seems that it has become a self -rescue path that many leading pharmaceutical companies have maintained research and development in recent years.
This kind of monkey has a special farm responsible for breeding. When the farm raises the monkey to the right age stage, it will sell it to pharmaceutical companies.
Experimental monkeys mainly buy some high -quality monkeys, and then continue to produce, and then receive a series of biological testing, which are included in some selection.
The agile monkeys in the zoo often attract children to watch. However, in addition to watching, the use of monkeys in medicine should not be underestimated. However, recently, the value of the monkeys has risen again and again, and many pharmaceutical companies shouted: “Can’t afford it!” According to the comprehensive report of Zhongxin Jingwei, due to the increased demand for research and development of pharmaceutical companies under the epidemic, coupled with the long cultivation cycle of monkey cultivation, and every time the cultivation cycle was cultivated, and every time the cultivation cycle was cultivated, and every time the cultivation cycle was cultivated, and every time the cultivation cycle was cultivated, each It can only be used for the study of one disease, which led to a 22 -fold increase in the price of experimental monkeys within 4 years, soaring from less than 7,000 yuan before, soaring to the current 160,000 yuan.
The relevant data shows that at present, there are only about 30,000 domestic experimental monkeys, and the voice of “valuable monkeys” in the market is getting louder. Affected by the “monkey shortage”, many companies began to hoard the monkey speed, and even bought the monkey field directly. It is reported that in 2020, Yaoming Kant’s wholly -owned subsidiary acquired the Guangdong Chunsheng Monkey Farm and harvested more than 20,000 crab and monkeys. According to the data of the Cat Cat, the registered capital of Wuxi Pharmaceutical Kant New Pharmaceutical Development Co., Ltd. is RMB 24,505.1572 yuan, and its operating business includes the development of research and approval of new drugs, medicine intermediates and fine chemical products (excluding dangerous chemicals) research and development (excluding dangerous chemicals) and many more.
In June 6, Zhaoyan New Pharmaceutical (603127.SH; 06127.HK) announced that Yingmao Bio became a wholly -owned subsidiary, and 20,000 experimental monkeys will gradually be returned to Zhao Yan Under the name of the new medicine. According to the data of Cat Cat, the registered capital of Beijing Zhaoyan New Pharmaceutical Research Center Co., Ltd. is 2708.2039 million yuan, and its business includes biological products, biotechnology technology development, technology transfer, and so on. There are only about 30,000 domestic experimental monkeys, and the voice of “valuable monkeys” in the market is getting louder. Affected by the “monkey shortage”, many companies began to hoard the monkey speed, and even bought the monkey field directly. At the expense of the blood speed of the monkey, in order to give self -sufficiency, it seems that it has become a self -rescue path that many leading pharmaceutical companies have maintained research and development in recent years.
This kind of monkey has a special farm responsible for breeding. When the farm raises the monkey to the right age stage, it will sell it to pharmaceutical companies.
This monkey is artificially raised, and there are specialized people to cultivate this monkey for experiments.
Experimental monkeys mainly buy some high -quality monkeys, and then continue to produce, and then receive a series of biological testing, which are included in some selection.